The Rs361525 and Rs2430561 Polymorphisms Are Associated with Liver Cirrhosis Risk: a Comprehensive Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 May 1

PMID 37122734

Authors

Minghui Zheng

Jing Li

Weizhen Fang

Ling Luo

Rui Ding

Hua Zeng

Hong Luo

Xianghua Lin

Chaohui Duan

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation serves as an essential driver of liver cirrhosis (LC) incidence. Accordingly, a meta-analysis was carried out to explore the association between specific polymorphisms in the interferon-γ () and tumor necrosis factor-α () genes and the incidence of LC based on comparisons of genotype and allele frequencies.

Objectives: To study the relationship between rs361525 and rs2430561 polymorphisms and the risk of LC.

Methods: A database search was performed for all studies published as of September 10, 2022. The strength of risk relationships was assessed based on odds ratios (ORs) with 95% confidence intervals (CIs).

Results: Pooled analyses were conducted for one common polymorphism (rs361525) as well as one common polymorphism (rs2430561). Both of these SNPs were identified as LC-related risk factors. Specifically, rs361525 was related to LC incidence in both alcoholic liver cirrhosis (OR: 1.86, 95%CI: 1.03-3.34) and hepatitis B virus (HBV)-related cirrhosis cases (OR: 1.44, 95%CI: 1.00-2.06) when using an allelic contrast model. Moreover, rs2430561 was significantly related to LC in an Asian population (OR: 1.45, 95%CI: 1.13-1.86) and in the context of HBV-related cirrhosis (OR: 1.48, 95%CI: 1.13-1.93) when using an allelic contrast model.

Conclusion: These findings indicate that rs361525 and rs2430561 represent LC-related risk factors, although additional large-scale clinical and case-control studies will be vital to confirm these results.

Citing Articles

Analysis of Mutational Status of , and Cytokine Polymorphisms as Prognostic Factors in Chronic Lymphocytic Leukemia: The Romanian Experience.

Balla B, Tripon F, Lazar E, Banescu C Int J Mol Sci. 2024; 25(3).

PMID: 38339076 PMC: 10855205. DOI: 10.3390/ijms25031799.

References

Bahgat N, Kamal M, Abdelaziz A, Mohye M, Shousha H, ahmed M . Interferon-γ and Interleukin-10 Gene Polymorphisms are not Predictors of Chronic Hepatitis C (Genotype-4) Disease Progression. Asian Pac J Cancer Prev. 2015; 16(12):5025-30. DOI: 10.7314/apjcp.2015.16.12.5025. View

Chen X, Zhou P, De L, Li B, Su S . The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects. Mol Genet Genomic Med. 2019; 7(8):e824. PMC: 6687636. DOI: 10.1002/mgg3.824. View

Stojsavljevic S, Gomercic Palcic M, Virovic Jukic L, Smircic Duvnjak L, Duvnjak M . Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 20(48):18070-91. PMC: 4277948. DOI: 10.3748/wjg.v20.i48.18070. View

Zhu H, Zhao H, Xu S, Zhang Y, Ding Y, Li J . Sennoside A alleviates inflammatory responses by inhibiting the hypermethylation of SOCS1 in CCl-induced liver fibrosis. Pharmacol Res. 2021; 174:105926. DOI: 10.1016/j.phrs.2021.105926. View

Shi J, Zhao J, Zhang X, Cheng Y, Hu J, Li Y . Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients. Sci Rep. 2017; 7:44544. PMC: 5349579. DOI: 10.1038/srep44544. View

Czaja A . Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol. 2014; 20(10):2515-32. PMC: 3949261. DOI: 10.3748/wjg.v20.i10.2515. View

Fan L, Zhong R, Tu X, Pfeiffer T, Feltens R, Zhu Y . [Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population]. Zhonghua Gan Zang Bing Za Zhi. 2004; 12(3):160-2. View

Sun Y, Lu Y, Xie L, Deng Y, Li S, Qin X . Interferon gamma polymorphisms and hepatitis B virus-related liver cirrhosis risk in a Chinese population. Cancer Cell Int. 2015; 15:35. PMC: 4389711. DOI: 10.1186/s12935-015-0184-2. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

10.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

11.

Bernal W, Moloney M, Underhill J, Donaldson P . Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol. 1999; 30(2):237-41. DOI: 10.1016/s0168-8278(99)80068-3. View

12.

Sghaier I, Zidi S, Mouelhi L, Dabbech R, Ghazouani E, Brochot E . The relationship between TNF alpha gene polymorphisms (-238/-308), TNF RII VNTR (p75) and outcomes of hepatitis B virus infection in Tunisian population. Gene. 2015; 568(2):140-5. DOI: 10.1016/j.gene.2015.05.029. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Zheng M, Fang W, Yu M, Ding R, Zeng H, Huang Y . IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis. BMC Endocr Disord. 2021; 21(1):242. PMC: 8656043. DOI: 10.1186/s12902-021-00906-3. View

15.

Morales-Mantilla D, King K . The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease. Curr Stem Cell Rep. 2018; 4(3):264-271. PMC: 6096761. DOI: 10.1007/s40778-018-0139-3. View

16.

Gordon M, OPPENHEIM E, Camp N, Di Giovine F, Duff G, Gleeson D . Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol. 1999; 31(2):242-7. DOI: 10.1016/s0168-8278(99)80220-7. View

17.

Sanchez Sanchez P, Del Mar Rigual M, Djouder N . Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers (Basel). 2021; 13(20). PMC: 8534267. DOI: 10.3390/cancers13205045. View

18.

Zhang S, Yang X, Wang W . Associations of genetic polymorphisms in CTLA-4 and IL-18 with chronic liver diseases: Evidence from a meta-analysis. Genomics. 2019; 112(2):1889-1896. DOI: 10.1016/j.ygeno.2019.11.001. View

19.

Yoon J, Gores G . Death receptor-mediated apoptosis and the liver. J Hepatol. 2002; 37(3):400-10. DOI: 10.1016/s0168-8278(02)00209-x. View

20.

Jones D, Watt F, Grove J, Newton J, Daly A, Gregory W . Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol. 1999; 30(2):232-6. DOI: 10.1016/s0168-8278(99)80067-1. View